{"prompt": "['11July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Clinical Trial Protocol', 'adopt', 'myasthenia', 'gravis study', 'Protocol Title:', 'A', 'Randomized,', 'Double-Blind,', 'Placebo-', 'Controlled, Multicenter Phase 3 Trial to Evaluate', 'the Efficacy, Safety and Tolerability of ARGX-113', 'in Patients with Myasthenia Gravis Having', 'Generalized Muscle Weakness', 'Protocol Number:', 'ARGX-113-1704 (ADAPT)', 'Date of Protocol:', '11 July 2019, Version 3.0, Final', 'Product:', 'ARGX-113', 'IND No:', 'CCI', 'EudraCT No:', '2018-002132-25', 'Trial Phase:', '3', 'Sponsor:', 'argenx BVBA', 'Industriepark Zwijnaarde 7', 'B-9052 Zwijnaarde', 'BELGIUM', 'Phone:', 'PPD', 'Medical Director:', 'PPD', 'argenx BVBA', 'Industriepark Zwijnaarde 7', 'B 9052 Zwijnaarde', 'BELGIUM', 'Phone: PPD', 'PPD', 'argenx BVBA', 'Confidential', 'Page 1 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Contract Research Organization', 'Syneos HealthTM group company', '(CRO):', 'including INC Research, LLC, together with INC', 'Research UK Limited', '3201 Beechleaf Court', 'Suite 600', 'Raleigh, North Carolina 27604-1547', 'US', 'Phone:', 'PPD', 'The following additional numbers are also available for urgent contact', '24 Hour Urgent Medical Helpline', 'PPD', 'Number:', 'For drug safety reporting, contact the below e-mail address', 'Safety Mailbox/Fax:', 'PPD', 'Confidentiality Statement', 'This confidential information in this document is provided to you as an Investigator or consultant for review', 'by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee. Your', 'acceptance of this document constitutes agreement that you will not disclose the information contained herein', 'to others without written authorization from the Sponsor.', 'argenx BVBA', 'Confidential', 'Page 2 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'SIGNATURES OF SPONSOR', 'PROTOCOL TITLE:', 'A Randomized, Double-Blind, Placebo-Controlled, Multicenter', 'Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of', 'ARGX-113 in Patients with Myasthenia Gravis Having', 'Generalized Muscle Weakness', 'PROTOCOL NO:', 'ARGX-113-1704 (ADAPT)', 'PPD', 'SPONSOR REPRESENTATIVE', '7/11/2019', 'PPD', 'Signature', 'Date', 'PPD', 'argenx BVBA', 'argenx BVBA', 'Confidential', 'Page 3 of 110']\n\n###\n\n", "completion": "END"}